CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement

Attanasio, Andrea F., Mo, Daojun, Erfurth, Eva Marie, Tan, Meng, Ho, Ken Y., Kleinberg, David, Zimmermann, Alan G., Chanson, Philippe · 2010 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT AND OBJECTIVE: Metabolic and body compositional consequences of GH deficiency (GHD) in adults are associated with a phenotype similar to the metabolic syndrome (MetS). PATIENTS: We assessed MetS prevalence in adult GHD patients (n = 2531) enrolled in the Hypopituitary Control and Complications Study. Prevalence was assessed at baseline and after 3 yr of GH replacement in a subset of 346 adult-onset patients. RESULTS: Baseline MetS crude prevalence was 42.3%; age-adjusted prevalence in the United States and Europe was 51.8 and 28.6% (P < 0.001), respectively. In the United States, age-adjusted prevalence was significantly higher (P < 0.001) than in a general population survey. Increased MetS risk at baseline was observed for age 40 yr or older (adjusted relative risk 1.34, 95% confidence interval 1.17-1.53, P < 0.001), females (1.15, 1.05-1.25, P = 0.002), and adult onset (1.77, 1.44-2.18, P < 0.001). In GH-treated adult-onset patients, MetS prevalence was not changed after 3 yr (42.5-45.7%, P = 0.172), but significant changes were seen for waist circumference (62.1-56.9%, P = 0.008), fasting glucose (26.0-32.4%, P < 0.001), and blood pressure (59.8-69.7%, P < 0.001). Significantly increased risk of MetS at yr 3 was associated with baseline MetS (adjusted relative risk 4.09, 95% confidence interval 3.02-5.53, P < 0.001) and body mass index 30 kg/m(2) or greater (1.53, 1.17-1.99, P = 0.002) and increased risk (with a P value < 0.1) for GH dose 600 microg/d or greater (1.18, 95% confidence interval 0.98-1.44, P = 0.088). CONCLUSION: MetS prevalence in GHD patients was higher than in the general population in the United States and higher in the United States than Europe. Prevalence was unaffected by GH replacement, but baseline MetS status and obesity were strong predictors of MetS after GH treatment.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2009-1326

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 47 references

Cited by

See all 117

Metadata

Authors
Attanasio, A. F., Mo, D., Erfurth, E. M., Tan, M., Ho, K. Y., Kleinberg, D., Zimmermann, A. G., & Chanson, P.
Affiliations
  • Eli Lilly (United States) (US)
  • Skåne University Hospital (SE)
  • New York University (US)
  • Université Paris-Sud (FR)
Corresponding author
Chanson, Philippe
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-01
Volume
95
Issue
1
Pages
74-81
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2122247204
Cited by
115
References
47
Citations by year
2026: 1 · 2025: 1 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 10 · 2018: 8 · 2017: 10 · 2016: 4 · 2015: 5 · 2014: 12 · 2013: 6 · 2012: 13
FWCI
7.00
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
metabolic syndrome, adult-onset growth hormone deficiency, growth hormone replacement therapy, hypopituitarism, prevalence, waist circumference, fasting blood glucose, blood pressure, body mass index, body composition, sex differences, obesity risk, cardiovascular risk factors, diabetes risk, dyslipidemia, hypertension, insulin resistance
MeSH terms
Adult, Aged, Female, Follow-Up Studies, Growth Disorders, Humans, Hypopituitarism, Male, Middle Aged, Obesity, Cohort Studies, Prevalence, Human Growth Hormone, Hormone Replacement Therapy, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement. https://app.cochat.ai/papers/10.1210/jc.2009-1326
The paper
Attanasio, A. F., Mo, D., Erfurth, E. M., Tan, M., Ho, K. Y., Kleinberg, D., Zimmermann, A. G., & Chanson, P. (2010). Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-1326

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.